Enhancing Renal Graft Function During Donor Anesthesia

NCT ID: NCT03778944

Last Updated: 2026-01-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-12-20

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Renal transplantation is now recognized as the treatment of choice for patients with end-stage renal disease. An optimum anesthetic regimen should enhance the function and perfusion of the transplanted kidney. The aim of this study is to assess \& compare the effectiveness of 3 different modalities in this respect: Mannitol, Dopamine and adequate hydration.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Renal Failure Chronic Transplant;Failure,Kidney Anesthesia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Using computer \& sealed envelope randomization, patients are assigned to receive either Mannitol \[M group; n=20\], Dopamine \[D group; n=20\] or adequate hydration \[C group; n=20\]
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

M group

Mannitol infusion

Group Type ACTIVE_COMPARATOR

Mannitol infusion

Intervention Type PROCEDURE

Infusion of Mannitol 20% at a dose of 0.5 mg/kg to the renal graft donor after induction of anesthesia over 15 minutes.

D group

Dopamine infusion

Group Type ACTIVE_COMPARATOR

Dopamine infusion

Intervention Type PROCEDURE

Infusion of Dopamine at a dose of 4 microg/kg/min to the renal graft donor after induction of anesthesia till ligation of the renal artery.

C group

Adequate hydration

Group Type ACTIVE_COMPARATOR

Adequate hydration

Intervention Type PROCEDURE

Infusion of Ringer Acetate at a rate of 15 ml/kg/hr to the renal graft donor after induction of anesthesia till ligation of the renal artery.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Mannitol infusion

Infusion of Mannitol 20% at a dose of 0.5 mg/kg to the renal graft donor after induction of anesthesia over 15 minutes.

Intervention Type PROCEDURE

Dopamine infusion

Infusion of Dopamine at a dose of 4 microg/kg/min to the renal graft donor after induction of anesthesia till ligation of the renal artery.

Intervention Type PROCEDURE

Adequate hydration

Infusion of Ringer Acetate at a rate of 15 ml/kg/hr to the renal graft donor after induction of anesthesia till ligation of the renal artery.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* end-stage renal disease, for living-donor kidney transplantation

Exclusion Criteria

* severe cardiac or hepatic dysfunction
* coagulopathy
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Nazmy Edward Seif

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Nazmy Edward Seif

Clinical Professor

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Nazmy E Seif, MD

Role: STUDY_CHAIR

Kasr Al-Ainy Hospital, Cairo University

Ahmed M Elbadawy, MD

Role: STUDY_DIRECTOR

Kasr Al-Ainy Hospital, Cairo University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kasr Al-Ainy Hospital, Cairo University

Cairo, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Nazmy E Seif, MD

Role: CONTACT

01227400808 ext. +2

Ahmed M Elbadawy, MD

Role: CONTACT

01064249076 ext. +2

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Nazmy E Seif, MD

Role: primary

01227400808 ext. +2

Ahmed M Elbadawy, MD

Role: backup

01064249076 ext. +2

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

RGFEDDA

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Donor Dopamine and Initial Graft Function
NCT00115115 COMPLETED PHASE4